Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378113 · ClinicalTrials.gov registry record · Phase 2
Ondansetron As a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
A Phase 2 study of Injection Site Irritation, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05378113 is a Phase 2 study of Injection Site Irritation that is actively recruiting participants, run by Emory University. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05378113, a Phase 2 study of Injection Site Irritation, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, single-site clinical trial that will take place at Children's Healthcare of Atlanta at Egleston. The investigators want to see if in pediatric patients, giving Zofran prior to propofol, reduces the pain that patients often experience when propofol is injected through an IV. Subjects will be randomized to 1 of 2 groups: lidocaine (common standard of care), or Zofran. The investigators hope to show a means of improving pain control in their patients undergoing anesthesia.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Lidocaine
Study Locations (1)
Georgia
- Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378113
The ClinicalTrials.gov registry entry for NCT05378113 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Injection Site Irritation appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron is the first listed.
NCT05378113 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05378113 about?
NCT05378113 is a clinical study titled "Ondansetron As a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial". This study is a randomized, single-site clinical trial that will take place at Children's Healthcare of Atlanta at Egleston. The investigators want to see if in pediatric patients, giving Zofran prior to propofol, reduces the pain that patients often experience when propofol is injected through an I...
What is the current status of trial NCT05378113?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2023-05-18. Estimated completion is 2025-12.
What conditions does trial NCT05378113 study?
This clinical trial studies the following conditions: Injection Site Irritation.
What interventions are being tested in trial NCT05378113?
The interventions under investigation include: Ondansetron (DRUG), Lidocaine (DRUG).
Who is sponsoring clinical trial NCT05378113?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378113 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.